Rising to the daily challenges of targeted oncology trials, Veristat joins leading pharma and biotech professionals working in the oncology clinical research at the Clinical Operations in Oncology West Coast 2018 conference.
DIA Europe 2018 | Catch Up With Veristat in Europe
March 8, 2018
Join Veristat and other drug development specialists at the DIA Europe Annual Meeting 2018 taking place in Basel, Switzerland. This event allows for the open collaboration of ideas and solutions needed to drive the progression of drug development. It brings together regulatory agencies, sponsors, patients and advocates to meet at the “crossroads of healthcare”, the theme at this year’s meeting.
Implementing an electronic Trial Master File (eTMF) isn’t as simple as it sounds, though having successfully implemented one last year makes Veristat’s Corporate Compliance leader the best person to learn from. And, she will be attending the 34th Annual Society of Quality Assurance Annual Meeting to share her insights and lessons learned from this implementation.
Webinar: Sponsors & CROs Explore CRO Consolidation
March 6, 2018
Veristat recently participated in the webinar titled "CRO Consolidation: A Sinister Threat or Windfall for Pharma?" View a recording of the webcast now.
MassBio Annual Meeting 2018 | Connect With Veristat
March 1, 2018
Every spring, Veristat attends and participates in the MassBio Annual Meeting and 2018 is no different. This year’s event will draw together more than 400 biopharma industry leaders and stakeholders to discuss timely and critical challenges facing the biopharma industry today, not only in Massachusetts, but around the world.
Medical Communication, MSL, and Medical Writing Forum
March 1, 2018
Members of the Veristat medical writing team will be at the DIA’s Medical Affairs and Scientific Communications Forum - Medical Communication, MSL, and Medical Writing. This forum will explore the best practices, newest technologies and the latest updates specific to scientific medical writing for clinical trials and regulatory submissions.